A survey of ex vivo/in vitro transduction efficiency of mammalian primary cells and cell lines with Nine natural adeno-associated virus (AAV1-9) and one engineered adeno-associated virus serotype

Virology Journal

Volumn 10, Issue , 2013, Pages

  Ellis, Brian L ^a   Hirsch, Matthew L ^b   Barker, Jenny C ^a   Connelly, Jon P ^a   Steininger, Robert J ^c   Porteus, Matthew H ^a,c  

^a UNIVERSITY OF TEXAS AT DALLAS   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

AAV; Adeno associated virus; Cell lines; ex vivo; Gene therapy; Primary cells; Progenitor cells; Serotypes; Transduction; Tropism

Indexed keywords

ADENO ASSOCIATED VIRUS; ANIMAL CELL; EX VIVO STUDY; FLOW CYTOMETRY; GENETIC ENGINEERING; GENETIC TRANSDUCTION; HUMAN; HUMAN CELL; IN VITRO STUDY; MAMMAL CELL; MOUSE; NONHUMAN; PRIMARY CELL CULTURE; REVIEW; SEROTYPE; VIRAL GENE DELIVERY SYSTEM; VIRUS GENOME; VIRUS INFECTION;

ANIMALS; CELL LINE; CELLS, CULTURED; CRICETINAE; DEPENDOVIRUS; GENETIC ENGINEERING; GENETIC THERAPY; GENETIC VECTORS; HAPLORHINI; HUMANS; MAMMALS; MICE; TRANSDUCTION, GENETIC; VIRAL TROPISM;

ADENO-ASSOCIATED VIRUS; MAMMALIA;

EID: 84874534423     PISSN: None     EISSN: 1743422X     Source Type: Journal    
DOI: 10.1186/1743-422X-10-74     Document Type: Review

References (59)

1. Gene therapy using adeno-associated virus vectors. Daya S, Berns KI, Clin Microbiol Rev 2008 21 583 593 10.1128/CMR.00008-08 18854481
2. Adeno-associated viral vectors and their redirection to cell-type specific receptors. Michelfelder S, Trepel M, Adv Genet 2009 67 29 60 19914449
3. A viral assembly factor promotes AAV2 capsid formation in the nucleolus. Sonntag F, Schmidt K, Kleinschmidt JA, Proc Natl Acad Sci U S A 2010 107 10220 10225 10.1073/pnas.1001673107 20479244
4. Second-strand synthesis is a rate-limiting step for efficient transduction by recombinant adeno-associated virus vectors. Ferrari FK, Samulski T, Shenk T, Samulski RJ, J Virol 1996 70 3227 3234 8627803 (Pubitemid 26121941)
5. Self-complementary recombinant adeno-associated virus (scAAV) vectors promote efficient transduction independently of DNA synthesis. McCarty DM, Monahan PE, Samulski RJ, Gene Ther 2001 8 1248 1254 10.1038/sj.gt.3301514 11509958 (Pubitemid 32780813)
6. Membrane-associated heparan sulfate proteoglycan is a receptor for adeno-associated virus type 2 virions. Summerford C, Samulski RJ, J Virol 1998 72 1438 1445 9445046 (Pubitemid 28116931)
7. Adeno-associated virus type 2 contains an integrin alpha5beta1 binding domain essential for viral cell entry. Asokan A, Hamra JB, Govindasamy L, Agbandje-McKenna M, Samulski RJ, J Virol 2006 80 8961 8969 10.1128/JVI.00843-06 16940508 (Pubitemid 44359970)
8. Hepatocyte growth factor receptor is a coreceptor for adeno-associated virus type 2 infection. Kashiwakura Y, Tamayose K, Iwabuchi K, Hirai Y, Shimada T, Matsumoto K, Nakamura T, Watanabe M, Oshimi K, Daida H, J Virol 2005 79 609 614 10.1128/JVI.79.1.609-614.2005 15596854 (Pubitemid 39648414)
9. CD9 promotes adeno-associated virus type 2 infection of mammary carcinoma cells with low cell surface expression of heparan sulphate proteoglycans. Kurzeder C, Koppold B, Sauer G, Pabst S, Kreienberg R, Deissler H, Int J Mol Med 2007 19 325 333 17203208
10. AlphaVbeta5 integrin: a co-receptor for adeno-associated virus type 2 infection. Summerford C, Bartlett JS, Samulski RJ, Nat Med 1999 5 78 82 10.1038/4768 9883843 (Pubitemid 29051002)
11. Human fibroblast growth factor receptor 1 is a co-receptor for infection by adeno-associated virus 2. Qing K, Mah C, Hansen J, Zhou S, Dwarki V, Srivastava A, Nat Med 1999 5 71 77 10.1038/4758 9883842 (Pubitemid 29051001)
12. The 37/67-kilodalton laminin receptor is a receptor for adeno-associated virus serotypes 8, 2, 3, and 9. Akache B, Grimm D, Pandey K, Yant SR, Xu H, Kay MA, J Virol 2006 80 9831 9836 10.1128/JVI.00878-06 16973587 (Pubitemid 44435657)
13. A two-hybrid screen identifies cathepsins B and L as uncoating factors for adeno-associated virus 2 and 8. Akache B, Grimm D, Shen X, Fuess S, Yant SR, Glazer DS, Park J, Kay MA, Mol Ther 2007 15 330 339 10.1038/sj.mt.6300053 17235311 (Pubitemid 46111883)
14. Adeno-associated virus serotype 4 (AAV4) and AAV5 both require sialic acid binding for hemagglutination and efficient transduction but differ in sialic acid linkage specificity. Kaludov N, Brown KE, Walters RW, Zabner J, Chiorini JA, J Virol 2001 75 6884 6893 10.1128/JVI.75.15.6884-6893.2001 11435568 (Pubitemid 32641575)
15. Adeno-associated virus types 5 and 6 use distinct receptors for cell entry. Seiler MP, Miller AD, Zabner J, Halbert CL, Hum Gene Ther 2006 17 10 19 10.1089/hum.2006.17.10 16409121 (Pubitemid 43100511)
16. Adeno-associated virus serotypes: vector toolkit for human gene therapy. Wu Z, Asokan A, Samulski RJ, Mol Ther 2006 14 316 327 10.1016/j.ymthe.2006.05. 009 16824801 (Pubitemid 44184972)
17. Alpha2,3 and alpha2,6 N-linked sialic acids facilitate efficient binding and transduction by adeno-associated virus types 1 and 6. Wu Z, Miller E, Agbandje-McKenna M, Samulski RJ, J Virol 2006 80 9093 9103 10.1128/JVI.00895-06 16940521 (Pubitemid 44359983)
18. Identification of PDGFR as a receptor for AAV-5 transduction. Di Pasquale G, Davidson BL, Stein CS, Martins I, Scudiero D, Monks A, Chiorini JA, Nat Med 2003 9 1306 1312 10.1038/nm929 14502277 (Pubitemid 37279855)
19. Analysis of AAV serotypes 1-9 mediated gene expression and tropism in mice after systemic injection. Zincarelli C, Soltys S, Rengo G, Rabinowitz JE, Mol Ther 2008 16 1073 1080 10.1038/mt.2008.76 18414476 (Pubitemid 351737072)
20. Zinc-finger nuclease-mediated gene correction using single AAV vector transduction and enhancement by Food and Drug Administration-approved drugs. Ellis BL, Hirsch ML, Porter SN, Samulski RJ, Porteus MH, Gene Ther 2013 1 35 42
21. Efficient gene targeting mediated by adeno-associated virus and DNA double-strand breaks. Porteus MH, Cathomen T, Weitzman MD, Baltimore D, Mol Cell Biol 2003 23 3558 3565 10.1128/MCB.23.10.3558-3565.2003 12724414 (Pubitemid 36539188)
22. Infection efficiency of human and mouse embryonic stem cells using adenoviral and adeno-associated viral vectors. Smith-Arica JR, Thomson AJ, Ansell R, Chiorini J, Davidson B, McWhir J, Cloning Stem Cells 2003 5 51 62 10.1089/153623003321512166 12713701 (Pubitemid 36418426)
23. Cross-dressing the virion: the transcapsidation of adeno-associated virus serotypes functionally defines subgroups. Rabinowitz JE, Bowles DE, Faust SM, Ledford JG, Cunningham SE, Samulski RJ, J Virol 2004 78 4421 4432 10.1128/JVI.78.9.4421-4432.2004 15078923 (Pubitemid 38501062)
24. Characterization of tissue tropism determinants of adeno-associated virus type 1. Hauck B, Xiao W, J Virol 2003 77 2768 2774 10.1128/JVI.77.4.2768-2774. 2003 12552020 (Pubitemid 36222804)
25. Marker rescue of adeno-associated virus (AAV) capsid mutants: a novel approach for chimeric AAV production. Bowles DE, Rabinowitz JE, Samulski RJ, J Virol 2003 77 423 432 10.1128/JVI.77.1.423-432.2003 12477847 (Pubitemid 36004982)
26. AAV hybrid serotypes: improved vectors for gene delivery. Choi VW, McCarty DM, Samulski RJ, Curr Gene Ther 2005 5 299 310 10.2174/1566523054064968 15975007 (Pubitemid 40895014)
27. Single amino acid changes can influence titer, heparin binding, and tissue tropism in different adeno-associated virus serotypes. Wu Z, Asokan A, Grieger JC, Govindasamy L, Agbandje-McKenna M, Samulski RJ, J Virol 2006 80 11393 11397 10.1128/JVI.01288-06 16943302 (Pubitemid 44706580)
28. Engineering and selection of shuffled AAV genomes: a new strategy for producing targeted biological nanoparticles. Li W, Asokan A, Wu Z, Van Dyke T, DiPrimio N, Johnson JS, Govindaswamy L, Agbandje-McKenna M, Leichtle S, Redmond DE Jr, McCown TJ, Petermann KB, Sharpless NE, Samulski RJ, Mol Ther 2008 16 1252 1260 10.1038/mt.2008.100 18500254 (Pubitemid 351866056)
29. Reengineering a receptor footprint of adeno-associated virus enables selective and systemic gene transfer to muscle. Asokan A, Conway JC, Phillips JL, Li C, Hegge J, Sinnott R, Yadav S, DiPrimio N, Nam HJ, Agbandje-McKenna M, McPhee S, Wolff J, Samulski RJ, Nat Biotechnol 2010 28 79 82 10.1038/nbt.1599 20037580
30. Directed evolution of a novel adeno-associated virus (AAV) vector that crosses the seizure-compromised blood-brain barrier (BBB). Gray SJ, Blake BL, Criswell HE, Nicolson SC, Samulski RJ, McCown TJ, Mol Ther 2010 18 570 578 10.1038/mt.2009.292 20040913
31. Directed evolution of adeno-associated virus yields enhanced gene delivery vectors. Maheshri N, Koerber JT, Kaspar BK, Schaffer DV, Nat Biotechnol 2006 24 198 204 10.1038/nbt1182 16429148 (Pubitemid 43221704)
32. Construction of diverse adeno-associated viral libraries for directed evolution of enhanced gene delivery vehicles. Koerber JT, Maheshri N, Kaspar BK, Schaffer DV, Nat Protoc 2006 1 701 706 10.1038/nprot.2006.93 17406299
33. Transposon-based mutagenesis generates diverse adeno-associated viral libraries with novel gene delivery properties. Koerber JT, Schaffer DV, Methods Mol Biol 2008 434 161 170 18470644
34. DNA shuffling of adeno-associated virus yields functionally diverse viral progeny. Koerber JT, Jang JH, Schaffer DV, Mol Ther 2008 16 1703 1709 10.1038/mt.2008.167 18728640
35. Surface immobilization of hexa-histidine-tagged adeno-associated viral vectors for localized gene delivery. Jang JH, Koerber JT, Gujraty K, Bethi SR, Kane RS, Schaffer DV, Gene Ther 2010 11 1384 1389
36. Designer gene delivery vectors: molecular engineering and evolution of adeno-associated viral vectors for enhanced gene transfer. Kwon I, Schaffer DV, Pharm Res 2008 25 489 499 10.1007/s11095-007-9431-0 17763830
37. Human gene targeting by viral vectors. Russell DW, Hirata RK, Nat Genet 1998 18 325 330 10.1038/ng0498-325 9537413 (Pubitemid 28158159)
38. Validation of AAV-mediated gene targeting. Russell DW, Hirata RK, Inoue N, Nat Biotechnol 2002 20 658 10.1038/nbt0702-658 12089544 (Pubitemid 34734127)
39. Gene targeting in vivo by adeno-associated virus vectors. Miller DG, Wang PR, Petek LM, Hirata RK, Sands MS, Russell DW, Nat Biotechnol 2006 24 1022 1026 10.1038/nbt1231 16878127 (Pubitemid 44215397)
40. Engineering of human pluripotent stem cells by AAV-mediated gene targeting. Khan IF, Hirata RK, Wang PR, Li Y, Kho J, Nelson A, Huo Y, Zavaljevski M, Ware C, Russell DW, Mol Ther 2010 18 1192 1199 10.1038/mt.2010.55 20407427
41. Human gene targeting by adeno-associated virus vectors is enhanced by DNA double-strand breaks. Miller DG, Petek LM, Russell DW, Mol Cell Biol 2003 23 3550 3557 10.1128/MCB.23.10.3550-3557.2003 12724413 (Pubitemid 36539187)
42. Self-complementary AAV mediates gene targeting and enhances endonuclease delivery for double-strand break repair. Hirsch ML, Green L, Porteus MH, Samulski RJ, Gene Ther 2010 9 1175 1180
43. Gene targeting using zinc finger nucleases. Porteus MH, Carroll D, Nat Biotechnol 2005 23 967 973 10.1038/nbt1125 16082368 (Pubitemid 41114030)
44. Efficient design and assembly of custom TALEN and other TAL effector-based constructs for DNA targeting. Cermak T, Doyle EL, Christian M, Wang L, Zhang Y, Schmidt C, Baller JA, Somia NV, Bogdanove AJ, Voytas DF, Nucleic Acids Res 2011 39 82 10.1093/nar/gkr218 21493687
45. Modularly assembled designer TAL effector nucleases for targeted gene knockout and gene replacement in eukaryotes. Li T, Huang S, Zhao X, Wright DA, Carpenter S, Spalding MH, Weeks DP, Yang B, Nucleic Acids Res 2011 39 6315 6325 10.1093/nar/gkr188 21459844
46. Genetic engineering of human pluripotent cells using TALE nucleases. Hockemeyer D, Wang H, Kiani S, Lai CS, Gao Q, Cassady JP, Cost GJ, Zhang L, Santiago Y, Miller JC, Nat Biotechnol 2011 29 731 734 10.1038/nbt.1927 21738127
47. Optimized TAL effector nucleases (TALENs) for use in treatment of sickle cell disease. Sun N, Liang J, Abil Z, Zhao H, Mol Biosyst 2012 8 1255 1263 10.1039/c2mb05461b 22301904
48. AAV8, 9, Rh10, Rh43 vector gene transfer in the rat brain: effects of serotype, promoter and purification method. Klein RL, Dayton RD, Tatom JB, Henderson KM, Henning PP, Mol Ther 2008 16 89 96 10.1038/sj.mt.6300331 17955025
49. Proteasome inhibitors decrease AAV2 capsid derived peptide epitope presentation on MHC class I following transduction. Finn JD, Hui D, Downey HD, Dunn D, Pien GC, Mingozzi F, Zhou S, High KA, Mol Ther 2010 18 135 142 10.1038/mt.2009.257 19904235
50. Viral single-strand DNA induces p53-dependent apoptosis in human embryonic stem cells. Hirsch ML, Fagan BM, Dumitru R, Bower JJ, Yadav S, Porteus MH, Pevny LH, Samulski RJ, PLoS One 2011 6 27520 10.1371/journal.pone.0027520 22114676
51. Production and characterization of adeno-associated viral vectors. Grieger JC, Choi VW, Samulski RJ, Nat Protoc 2006 1 1412 1428 10.1038/nprot.2006.207 17406430
52. Absence of cancer-associated changes in human fibroblasts immortalized with telomerase. Morales CP, Holt SE, Ouellette M, Kaur KJ, Yan Y, Wilson KS, White MA, Wright WE, Shay JW, Nat Genet 1999 21 115 118 10.1038/5063 9916803 (Pubitemid 29036296)
53. Immortalization of human bronchial epithelial cells in the absence of viral oncoproteins. Ramirez RD, Sheridan S, Girard L, Sato M, Kim Y, Pollack J, Peyton M, Zou Y, Kurie JM, Dimaio JM, Cancer Res 2004 64 9027 9034 10.1158/0008-5472.CAN-04-3703 15604268 (Pubitemid 39665513)
54. Gene Correction by Homologous Recombination With Zinc Finger Nucleases in Primary Cells From a Mouse Model of a Generic Recessive Genetic Disease. Connelly JP, Barker JC, Pruett-Miller S, Porteus MH, Mol Ther 2010 6 1103 1110
55. Isolation and short-term culture of primary keratinocytes, hair follicle populations and dermal cells from newborn mice and keratinocytes from adult mice for in vitro analysis and for grafting to immunodeficient mice. Lichti U, Anders J, Yuspa SH, Nat Protoc 2008 3 799 810 10.1038/nprot.2008.50 18451788 (Pubitemid 351639024)
56. Murine marrow-derived mesenchymal stem cell: isolation, in vitro expansion, and characterization. Meirelles Lda S, Nardi NB, Br J Haematol 2003 123 702 711 10.1046/j.1365-2141.2003.04669.x 14616976 (Pubitemid 37468069)
57. Highly efficient, functional engraftment of skeletal muscle stem cells in dystrophic muscles. Cerletti M, Jurga S, Witczak CA, Hirshman MF, Shadrach JL, Goodyear LJ, Wagers AJ, Cell 2008 134 37 47 10.1016/j.cell.2008.05.049 18614009 (Pubitemid 351905744)
58. White fat progenitor cells reside in the adipose vasculature. Tang W, Zeve D, Suh JM, Bosnakovski D, Kyba M, Hammer RE, Tallquist MD, Graff JM, Science 2008 322 583 586 10.1126/science.1156232 18801968
59. Glucose-stimulated insulin secretion is coupled to the interaction of actin with the t-SNARE (target membrane soluble N-ethylmaleimide-sensitive factor attachment protein receptor protein) complex. Thurmond DC, Gonelle-Gispert C, Furukawa M, Halban PA, Pessin JE, Mol Endocrinol 2003 17 732 742 10.1210/me.2002-0333 12554769 (Pubitemid 36403583)